<DOC>
	<DOCNO>NCT03028103</DOCNO>
	<brief_summary>This Phase 1 , open-label , two-part , safety , PK , activity study design characterize DDI potential tazemetostat . Tazemetostat take orally BID continuously 28-day cycle study part .</brief_summary>
	<brief_title>Open-Label , Multicenter , Two-Part , Phase 1 Study Characterize Effects Moderate CYP3A Inhibitor PK Tazemetostat , Effects Tazemetostat PK CYP2C8 CYP2C19 Substrates , Effect Increased Gastric pH PK Tazemetostat B-cell Lymphoma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<criteria>Inclusion criterion 1 . Male female ≥ 18 year age time consent 2 . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 3 . Has histologically confirm diffuse large Bcell lymphoma ( DLBCL ) , primary mediastinal Bcell lymphoma ( PMBCL ) mantle cell lymphoma ( MCL ) relapse refractory disease follow least two line prior standard therapy , include alkylator/anthracycline ( unless anthracyclinebased chemotherapy contraindicate ) /antiCD20based therapy ( RCHOP ; rituximab , doxorubicin , cyclophosphamide , vincristine , prednisolone prednisone , equivalent ) AND must consider unable benefit intensification treatment autologous hematopoietic stem cell transplantation ( ASCT ) , define meeting least one follow criterion : 1 . Relapsed follow , refractory , previous ASCT 2 . Did achieve least partial response ( PR ) standard salvage regimen ( e.g. , RICE ; rituximab , ifosfamide , carboplatin , etoposide , RDHAP ; rituximab , dexamethasone , cytarabine , cisplatin ) 3 . Ineligible intensification treatment due age significant comorbidity 4 . Ineligible intensification treatment due failure mobilize acceptable number hematopoietic stem cell 5 . Refused intensification treatment and/or ASCT 4 . Transformed disease permit 5 . Must evaluable measurable disease 6 . Has prior treatment ( i.e. , chemotherapy , immunotherapy , radiotherapy ) relate clinically significant toxicity resolve ≤ Grade 1 per NCI CTCAE , Version 4.03 clinically stable clinically significant , time consent 7 . Time require last dose late therapy first dose study drug : 1 . Chemotherapy : cytotoxic At least 21 day 2 . Chemotherapy : nitrosoureas At least 6 week 3 . Chemotherapy : noncytotoxic ( e.g. , small molecule inhibitor ) At least 14 day 4 . Monoclonal antibody ( y ) At least 28 day 5 . Nonantibody immunotherapy ( e.g. , tumor vaccine ) At least 42 day 6 . Radiotherapy ( RT ) At least 14 day local site RT 7 . At least 21 day stereotactic radiosurgery 8 . At least 12 week craniospinal , ≥50 % radiation pelvis , total body irradiation prior first dose study drug 9 . Autologous hematopoietic cell infusion high dose therapy At least 60 day 10 . Hematopoietic growth factor At least 14 day 8 . Has adequate hematologic ( bone marrow [ BM ] coagulation factor ) , renal hepatic function 1 . Hemoglobin ≥9 g/dL 2 . Platelets ≥75,000/mm3 ( ≥75 × 10^9/L ) 3 . ANC ≥750/mm3 ( ≥0.75 × 10^9/L ) 4 . PT &lt; 1.5 ULN 5 . PTT &lt; 1.5 ULN 6. eGFR ≥ 50 mL/min/1.73 m2 7 . Conjugated bilirubin &lt; 1.5 × ULN 8 . AST &lt; 3 × ULN 9 . ALT &lt; 3 × ULN NOTE : Laboratory result obtain screen use determine eligibility criterion . In situation laboratory result outside permitted range , investigator may retest subject subsequent within range screen result may use determine subject 's eligibility . 9 . Has QT interval correct Fridericia 's formula ( QTcF ) ≤480 msec 10 . Subjects history Hepatitis B C eligible condition subject adequate liver function define protocol hepatitis B surface antigen negative and/or undetectable HCV RNA . 11 . Male subject must refrain donate sperm start plan first dose investigational product ( IP ) 30 day follow last dose IP 12 . Male subject female partner childbearing potential must : 1 . Be vasectomize , 2 . Remain abstinent use condom define Section 8.3.8.4.2 , start plan first dose IP 30 day follow last dose IP . The reliability sexual abstinence evaluate relation duration clinical trial prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . 13 . Female partner male subject childbearing potential must also adhere one following : 1 . Placement intrauterine device intrauterine system . 2 . Established use oral , injected , implanted hormonal method contraception . 3 . Progesterone oral contraception , inhibition ovulation primary mode action . 14 . Women childbearing potential female partner male subject must abide contraception measure define protocol Exclusion criterion : 1 . Is pregnant nurse 2 . Has active central nervous system ( CNS ) leptomeningeal metastasis 3 . Has prior malignancy malignancy study Exception : Subject diseasefree 3 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . 4 . Has major surgery within 3 week prior enrollment NOTE : Minor surgery ( e.g. , minor biopsy , central venous catheter placement ) permit within 3 week prior enrollment . 5 . Is unwilling exclude grapefruit juice , Seville oranges , grapefruit diet food contain fruits time enrollment study 6 . Has cardiovascular impairment , history congestive heart failure great NYHA Class II uncontrolled arterial hypertension , unstable angina , myocardial infarction , stroke within 6 month prior plan first dose tazemetostat ; ventricular cardiac arrhythmia require medical treatment 7 . Subjects take medication know potent moderate inducers/ inhibitor CYP3A4 ( include St. John 's Wort ) 8 . Has active infection recent history ( &lt; 30 day study drug administration ) require systemic treatment 9 . Is immunocompromised , include subject know human immunodeficiency virus ( HIV ) infection 10 . Has know hypersensitivity component IP . 11 . Is unable take oral medication , history surgery would interfere administration absorption oral medication , malabsorption syndrome uncontrolled gastrointestinal condition ( e.g. , nausea , diarrhea vomit ) might impair bioavailability IP 12 . Has uncontrolled intercurrent illness include , limited , uncontrolled infection , psychiatric illness/social situation would limit compliance study requirement . 13 . Is unwilling adhere contraception criterion time enrollment study least 30 day last dose IP . 14 . A history bleeding ( i.e. , hemoptysis , hematuria , gastrointestinal blood loss , epistaxis , others great Grade 1 accord NCI CTCAE Version 4.03 ) within 1 month prior begin therapy clinical indication current active bleeding . 15 . Clinical history , current alcohol ( ethanol ) , illicit drug use , judgment investigator , interfere subject 's ability comply dose schedule protocolspecified evaluation . 16 . Regular alcohol consumption average seven drinks/week woman 14 drinks/week men within 6 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>